首頁 > 市場調查報告書 > 製藥

非專利藥

市場調查報告書

商品編碼

1461321

非專利無菌注射劑市場：依藥物類型、治療應用、通路、地區

Generic Sterile Injectables Market, by Drug Type, by Therapeutic Application, by Distribution Channel and by Region

出版日期: 2024年03月11日 | 出版商:

Coherent Market Insights | 英文 387 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

至2024年，全球非專利藥無菌注射劑市場估計為463.3億美元，預計在預測期內（2024-2031年）年複合成長率為10.3%。

報告範圍		報告詳情
基準年	2023年	2023/2024年市場規模	463.3億美元
實際資料	2019-2023	預測期	2024-2031
預測期2023/2024-2030/2031年複合成長率	10.30%	2030/2031 年預測值	919.1億美元

2024 年全球非專利藥無菌注射劑市場規模（十億美元）（按地區）

非專利無菌注射是美國FDA核准的生技藥品，在醫療產業的大部分領域用於治療許多疾病和病症。非專利無菌注射劑比這些藥物的品牌版本便宜得多，而且效果也一樣。因此，這些注射劑的需求量始終很高，並被世界各地的大多數醫院和診所使用。然而，由於FDA對這些注射劑的生產有嚴格的規定，這些注射劑的嚴格需求滿足一直是全球非專利藥無菌注射劑市場主要參與企業面臨的一個挑戰。

隨著無菌注射劑適用於各種疾病和醫療狀況，非專利無菌注射市場預計在可預見的未來將獲得穩定的發展。製造商正致力於增加非專利無菌注射劑的產量，以滿足不斷成長的需求，同時又不影響注射劑的品質。

市場動態

市場參與企業正在致力於推出非專利無菌注射劑的新產品，預計這將在預測期內促進全球非專利無菌注射劑的成長。例如，2017年6月，百特國際公司推出了可立即使用的克林黴素鹽水注射液，其三種常用處方配方為：300 mg/50 mL、600 mg/50 mL和900 mg/50 mL ，美國FDA商業性核准該產品。克林黴素是一種抗生素，通常用於治療由敏感厭氧和鏈球菌、肺炎球菌和葡萄球菌菌株引起的嚴重感染疾病，而青黴素不適合患者。

主要企業正專注於合作夥伴關係等無機活動，預計這將在預測期內促進全球非專利藥無菌注射劑市場的成長。例如，2017年，諾華公司的非專利部門山德士擴大了在斯洛維尼亞的抗生素工廠，投資超過3,354萬美元來開發和現代化該工廠。第一條生產線將於 2019 年啟動，新生產線將於 2023 年分階段投入使用。

該公司專注於採用收購等無機成長策略，以擴大其全球影響力並改善其國際商機。例如，2016年8月，梯瓦製藥工業有限公司完成了對艾爾建學名藥業務的收購。艾爾建公司是一家總部位於愛爾蘭的美國製藥公司。

本研究的主要特點

該報告對全球非專利藥無菌注射劑市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、區域前景、主要企業採取的競爭策略等的重要見解。
它根據公司簡介、財務績效、產品系列、地理分佈、分銷策略、關鍵發展和策略以及未來計劃等參數，介紹了全球非專利無菌注射劑市場的主要企業。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、技術改進、市場擴張和行銷策略做出明智的決策。
全球非專利無菌注射劑市場報告針對該行業的各個相關人員，如投資者、供應商、製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球非專利無菌注射劑市場的各種策略矩陣來促進他們的決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲
歐洲
德國
英國
法國
義大利
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
澳洲
韓國
東南亞國協
其他亞太地區
中東
波灣合作理事會
以色列
其他中東地區
非洲
南非
中部非洲
北非

第9章競爭格局

公司簡介
- Baxter International Inc.
- AstraZeneca plc
- Merck &Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan NV
- Sun Pharmaceutical Industries Ltd.

第10章分析師建議

繁榮與衰落
綜合機會圖

第11章章節

參考
調查方法

簡介目錄

Product Code: CMI519

Global generic sterile injectables market is estimated to be valued at USD 46.33 Bn in 2024 and is expected to exhibit a CAGR of 10.3% during the forecast period (2024-2031).

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 46.33 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	10.30%	2030/2031 Value Projection:	US$ 91.91 Bn

Global Generic Sterile Injectables Market Value (US$ Bn), by Region, 2024

Generic Sterile Injectables Market - IMG1

The generic sterile injectable are U.S. FDA approved biologics that are used for the treatment of many diseases and disorders in the vast arena of the healthcare industry. The generic sterile injectable are very inexpensive as compared to that of their branded counterparts of these drugs and performs equally well. Thus, these Injectables are heavily in demand all the time and are used in majority of hospitals and clinics across the globe. However, due to the stringent FDA regulations for the production of these injectable, the rigorous demand satisfaction of these injectable has always been a constant challenge for the key players in the global generic sterile injectable market.

The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.

Market Dynamics

Market players are engaged in launching new products for generic sterile injectables, this is expected to increase the growth of the global generic sterile injectables, over the forecast period. For instance, in June 2017, Baxter International Inc. announced the U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations (300mg/50mL, 600mg/50mL, and 900mg/50mL). Clindamycin is a widely prescribed antibiotic for serious infections which is caused by susceptible anaerobic bacteria and strains of streptococci, pneumococci and staphylococci, when penicillin is inappropriate for a patient.

Key players are focusing on inorganic activities such as partnerships, this is expected to increase the growth of the global generic sterile injectables market, over the forecast period. For instance, in 2017, Novartis' generic arm Sandoz expanded its antibiotic facility in Slovenia, with an investment of over US$ 33.54 million aimed at the development and modernization of facilities. The first production lines started in 2019, after which new lines will be gradually phased in by 2023.

The company is focused on adopting inorganic growth strategies such as acquisitions to expand its global presence and improve international commercial opportunities. For instance, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business. Allergan plc.is an American, Irish-domiciled pharmaceutical company.

Key features of the study:

This report provides an in-depth analysis of the global generic sterile injectables market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global generic sterile injectables market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., and Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global generic sterile injectables market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global generic sterile injectables market

Detailed Segmentation:

Global Generic Sterile Injectables Market, By Drug Type:
- Monoclonal Antibodies
- Cytokines
- Insulin
- Peptide Hormones
- Vaccines
- Immunoglobulins
- Blood Factors
- Antibiotics
- Others
Global Generic Sterile Injectables Market, By Therapeutic Application:
- Cancer
- Metabolic Diseases
- Cardiovascular Diseases
- Central Nervous System Disease
- Infectious Disorders
- Musculoskeletal Disorders
- Others
Global Generic Sterile Injectables Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Generic Sterile Injectables Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Baxter International Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Scenario
PEST Analysis
Recent Product Launch/Approval
Epidemiology
Mergers and Acquisitions

4. Global Generic Sterile Injectables Market - Impact of Coronavirus (Covid-19) Pandemic

Impact on Supply Chain
Impact on Research and Development
Government Initiatives

5. Global Generic Sterile Injectables Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Blood Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)

6. Global Generic Sterile Injectables Market, By Therapeutic Application, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Metabolic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Central Nervous System Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Infectious Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Musculoskeletal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)

7. Global Generic Sterile Injectables Market, By Distribution Channel, 2019 - 2031 (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)

8. Global Generic Sterile Injectables Market, By Region, 2019 - 2031 (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019 - 2031
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Company Profiles
- Baxter International Inc.
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- AstraZeneca plc
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Merck & Co., Inc.
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Pfizer Inc.
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.